Free Trial

Acumen Pharmaceuticals (ABOS) SEC Filings & 10K Form

Acumen Pharmaceuticals logo
$1.18 -0.09 (-7.09%)
Closing price 04:00 PM Eastern
Extended Trading
$1.19 +0.01 (+1.19%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Acumen Pharmaceuticals SEC Filings

DateFilerForm TypeView
06/05/2025
5:05 PM
Acumen Pharmaceuticals (Issuer)
Stoppel Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
5:12 PM
Acumen Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
3:51 PM
Acumen Pharmaceuticals (Issuer)
Porter Derrell (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
3:52 PM
Acumen Pharmaceuticals (Issuer)
Ives Jeffrey L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
3:57 PM
Acumen Pharmaceuticals (Issuer)
Drapkin Kimberlee C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
3:57 PM
Acumen Pharmaceuticals (Issuer)
Fountain Nathan B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
3:59 PM
Acumen Pharmaceuticals (Issuer)
Stalfort John A III (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025
3:36 PM
Acumen Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/13/2025
6:32 AM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2025
3:57 PM
Acumen Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SCHEDULE 13D/A
03/27/2025
3:34 PM
Acumen Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/27/2025
3:38 PM
Acumen Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/27/2025
6:24 AM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/23/2025
8:19 PM
Acumen Pharmaceuticals (Issuer)
Zuga Matt (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:14 PM
Acumen Pharmaceuticals (Issuer)
Barton Russell (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:16 PM
Acumen Pharmaceuticals (Issuer)
Meisner Derek M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:18 PM
Acumen Pharmaceuticals (Issuer)
OConnell Daniel Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:06 PM
Acumen Pharmaceuticals (Issuer)
Siemers Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
3:17 PM
Acumen Pharmaceuticals (Subject)
Zuga Matt (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:31 PM
Acumen Pharmaceuticals (Subject)
Siemers Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:32 PM
Acumen Pharmaceuticals (Subject)
Meisner Derek M (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:24 PM
Acumen Pharmaceuticals (Subject)
OConnell Daniel Joseph (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:25 PM
Acumen Pharmaceuticals (Subject)
Zuga Matt (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/07/2025
6:57 PM
Acumen Pharmaceuticals (Issuer)
Meisner Derek M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
7:00 PM
Acumen Pharmaceuticals (Issuer)
Doherty James J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
7:02 PM
Acumen Pharmaceuticals (Issuer)
Schacterle Amy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
7:09 PM
Acumen Pharmaceuticals (Issuer)
OConnell Daniel Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
6:48 PM
Acumen Pharmaceuticals (Issuer)
Siemers Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
6:53 PM
Acumen Pharmaceuticals (Issuer)
Zuga Matt (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
6:55 PM
Acumen Pharmaceuticals (Issuer)
Barton Russell (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
5:16 PM
Acumen Pharmaceuticals (Subject)
Meisner Derek M (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
4:54 PM
Acumen Pharmaceuticals (Subject)
Zuga Matt (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
4:59 PM
Acumen Pharmaceuticals (Subject)
Barton Russell (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
5:04 PM
Acumen Pharmaceuticals (Subject)
Siemers Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/06/2024
4:24 PM
Acumen Pharmaceuticals (Issuer)
Schacterle Amy (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/06/2024
4:27 PM
Acumen Pharmaceuticals (Issuer)
Schacterle Amy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:42 PM
Acumen Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/13/2024
6:48 AM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2024
4:26 PM
Acumen Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:40 PM
Acumen Pharmaceuticals (Issuer)
Drapkin Kimberlee C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:41 PM
Acumen Pharmaceuticals (Issuer)
Fountain Nathan B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Trump set to Boost Social Security Checks by 400%? (Ad)

If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...

Click here to see the details because the stakes couldn't be any higher.
06/10/2024
3:46 PM
Acumen Pharmaceuticals (Issuer)
Porter Derrell (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:49 PM
Acumen Pharmaceuticals (Issuer)
Stalfort John A III (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:51 PM
Acumen Pharmaceuticals (Issuer)
Stoppel Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ABOS) was last updated on 6/10/2025 by MarketBeat.com Staff
From Our Partners